» Articles » PMID: 37130728

Association of Serum Neurofilament Light with Microglial Activation in Multiple Sclerosis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Translocator protein (TSPO)-PET and neurofilament light (NfL) both report on brain pathology, but their potential association has not yet been studied in multiple sclerosis (MS) in vivo. We aimed to evaluate the association between serum NfL (sNfL) and TSPO-PET-measurable microglial activation in the brain of patients with MS.

Methods: Microglial activation was detected using PET and the TSPO-binding radioligand [C]PK11195. Distribution volume ratio (DVR) was used to evaluate specific [C]PK11195-binding. sNfL levels were measured using single molecule array (Simoa). The associations between [C]PK11195 DVR and sNfL were evaluated using correlation analyses and false discovery rate (FDR) corrected linear regression modelling.

Results: 44 patients with MS (40 relapsing-remitting and 4 secondary progressive) and 24 age-matched and sex-matched healthy controls were included. In the patient group with elevated brain [C]PK11195 DVR (n=19), increased sNfL associated with higher DVR in the lesion rim (estimate (95% CI) 0.49 (0.15 to 0.83), p(FDR)=0.04) and perilesional normal appearing white matter (0.48 (0.14 to 0.83), p(FDR)=0.04), and with a higher number and larger volume of TSPO-PET-detectable rim-active lesions defined by microglial activation at the plaque edge (0.46 (0.10 to 0.81), p(FDR)=0.04 and 0.50 (0.17 to 0.84), p(FDR)=0.04, respectively). Based on the multivariate stepwise linear regression model, the volume of rim-active lesions was the most relevant factor affecting sNfL.

Conclusions: Our demonstration of an association between microglial activation as measured by increased TSPO-PET signal, and elevated sNfL emphasises the significance of smouldering inflammation for progression-promoting pathology in MS and highlights the role of rim-active lesions in promoting neuroaxonal damage.

Citing Articles

Transcriptomic profiling identifies ferroptosis and NF-κB signaling involved in α-dimorphecolic acid regulation of microglial inflammation.

Zhu X, Wang P, Chao S, Tang W, Zhao L, Yu L J Transl Med. 2025; 23(1):260.

PMID: 40038710 PMC: 11877847. DOI: 10.1186/s12967-025-06296-7.


Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway.

Li B, Yu K, Zhou X, Sun J, Qi L, Li W J Headache Pain. 2025; 26(1):16.

PMID: 39871133 PMC: 11771075. DOI: 10.1186/s10194-025-01953-0.


Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance.

Dal-Bianco A, Oh J, Sati P, Absinta M Ther Adv Neurol Disord. 2024; 17():17562864241306684.

PMID: 39711984 PMC: 11660293. DOI: 10.1177/17562864241306684.


Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.

Toorop A, Wessels M, Boonkamp L, Gelissen L, Hoitsma E, Zeinstra E Mult Scler. 2024; 30(13):1683-1688.

PMID: 39494701 PMC: 11568651. DOI: 10.1177/13524585241293940.


Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals.

Laaksonen S, Saraste M, Nylund M, Hinz R, Snellman A, Rinne J Front Neurol. 2024; 15:1352116.

PMID: 38445263 PMC: 10913932. DOI: 10.3389/fneur.2024.1352116.

References
1.
Gillen K, Mubarak M, Nguyen T, Pitt D . Significance and Detection of Iron-Laden Microglia in White Matter Multiple Sclerosis Lesions. Front Immunol. 2018; 9:255. PMC: 5826076. DOI: 10.3389/fimmu.2018.00255. View

2.
Howell O, Rundle J, Garg A, Komada M, Brophy P, Reynolds R . Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol. 2010; 69(10):1017-1033. PMC: 4335193. DOI: 10.1097/NEN.0b013e3181f3a5b1. View

3.
Dal-Bianco A, Schranzer R, Grabner G, Lanzinger M, Kolbrink S, Pusswald G . Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study. Front Neurol. 2022; 12:632749. PMC: 8724313. DOI: 10.3389/fneur.2021.632749. View

4.
Maggi P, Kuhle J, Schadelin S, van der Meer F, Weigel M, Galbusera R . Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology. 2021; 97(6):e543-e553. PMC: 8424501. DOI: 10.1212/WNL.0000000000012326. View

5.
Kuhle J, Kropshofer H, Haering D, Kundu U, Meinert R, Barro C . Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019; 92(10):e1007-e1015. PMC: 6442011. DOI: 10.1212/WNL.0000000000007032. View